Product image of Levonis Adulti (Flunisolide) supplied by GNH India

Levonis Adulti

Active Ingredient:
Flunisolide
Origin:
EU

Levonis Adulti (Flunisolide)

Flunisolide, the active ingredient in Levonis Adulti, is a glucocorticoid presented as an inhalation formulation for inhalation use. It reduces airway inflammation and is indicated for the management of asthma and allergic rhinitis in adult patients.

GNH India supplies Levonis Adulti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive technical support, documentation, and timely delivery across multiple continents.

Manufacturer / TM Owner

Farto S.R.L. Farmaco Biochimico Toscano

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Flunisolide is a glucocorticoid used to manage inflammatory airway conditions.
  • Asthma: reduces airway hyperresponsiveness and inflammation, improving breathing control.
  • Allergic rhinitis: alleviates nasal congestion, sneezing and itching by decreasing mucosal inflammation.
  • Seasonal allergic rhinitis: provides symptom relief during pollen seasons by suppressing allergic airway responses.

How It Works

  • Flunisolide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and interacts with glucocorticoid response elements. This modulates gene transcription, leading to decreased production of pro‑inflammatory cytokines, reduced recruitment of inflammatory cells, and suppression of immune responses within the airway mucosa.

Side Effects

Flunisolide may cause a range of adverse reactions, most of which are related to its local anti‑inflammatory activity in the respiratory tract.

Common Side Effects

  • Oral thrush (candidiasis)
  • Hoarseness or dysphonia
  • Cough or throat irritation
  • Headache
  • Nasal dryness
  • Mild epistaxis

Serious or Rare Side Effects

  • Adrenal suppression
  • Osteoporosis with long‑term use
  • Cataracts or glaucoma
  • Severe allergic reaction (anaphylaxis)
  • Immunosuppression leading to opportunistic infections
  • Hyperglycemia in susceptible individuals

Precautions & Warnings

  • When prescribing or dispensing Levonis Adulti, consider the following safety measures.
  • Assess for active respiratory infection before initiating therapy.
  • Monitor for signs of oral candidiasis and advise proper oral hygiene.
  • Use a spacer device to reduce oropharyngeal deposition.
  • Avoid abrupt discontinuation; taper dose when long‑term therapy is stopped.
  • Pregnancy safety is unknown; weigh benefits against potential risks.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Flunisolide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Systemic corticosteroids: additive immunosuppressive effects.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic exposure.
  • Live vaccines: risk of reduced vaccine efficacy and infection.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels.
  • Diuretics: potential for fluid retention and electrolyte imbalance.
  • Beta‑agonist bronchodilators: possible reduced bronchodilator response.

Frequently Asked Questions

Levonis Adulti contains flunisolide, an inhaled glucocorticoid that is prescribed for the management of asthma and allergic rhinitis in adult patients. It works by reducing inflammation in the airways and nasal passages, helping to control symptoms such as wheezing, shortness of breath, nasal congestion, and sneezing.

Flunisolide binds to glucocorticoid receptors inside airway cells. The drug‑receptor complex then moves to the cell nucleus where it influences gene transcription, decreasing the production of inflammatory cytokines and limiting the recruitment of immune cells. This results in reduced airway inflammation and improved airflow.

The dose of Levonis Adulti is individualized by the prescribing healthcare professional based on the severity of the condition, patient age, and response to therapy. The prescriber determines the appropriate inhalation strength, frequency, and duration, and patients should follow the written prescription exactly.

Safety data for flunisolide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women.

To request Levonis Adulti, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. The sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Levonis Adulti (flunisolide) is an inhaled glucocorticoid similar in class to budesonide, beclomethasone and fluticasone. All act by reducing airway inflammation, but differences exist in potency, particle size, and dosing frequency. Flunisolide is often selected for its specific pharmacokinetic profile and suitability for certain patient populations.

Levonis Adulti should be stored at room temperature, below 25 °C, in its original packaging. Keep the inhaler away from moisture, excessive heat, and direct sunlight to maintain product stability and efficacy.

Levonis Adulti is delivered via inhalation using a metered‑dose inhaler or a dry‑powder inhaler, as specified by the prescriber. Patients should inhale the dose slowly and may use a spacer device to improve drug deposition and reduce oropharyngeal side effects.

Serious risks, although uncommon, include adrenal suppression, osteoporosis with long‑term use, cataracts or glaucoma, and severe allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of these conditions, especially when high doses are used over extended periods.

Levonis Adulti is contraindicated in individuals with a known hypersensitivity to flunisolide or any component of the inhaler. It should also be avoided in patients with active, untreated infections of the respiratory tract unless the benefits outweigh the risks, and in those for whom systemic corticosteroids are contraindicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Flunisolide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT